Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) received conditional TSX Venture Exchange approval to acquire approximately 54% of CliniQuantum.
The deal involves issuing 56,600,000 NeuroThera shares, valued at about $9.46 million, escrowed under TSX policies, with amended SPA terms including a $0.05 floor price for earn-out shares and an extended outside closing date to June 1, 2026.
SciSparc (Nasdaq: SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, is collaborating with Clearmind Medicine on a patent application filed in Hong Kong for a novel MEAI‑PEA combination therapy aimed at treating major depressive disorder.
The filing describes a non‑hallucinogenic neuroplastogen approach combining Clearmind’s MEAI with Palmitoylethanolamide (PEA) sourced by NeuroThera. According to the filing context, the therapy targets depression, which affects > 332 million people worldwide per WHO (Aug 2025).
SciSparc (Nasdaq: SPRC) said NeuroThera Labs (TSXV: NTLX), in which SciSparc holds a controlling interest of ~75%, advanced a collaboration with Clearmind via publication of a PCT international patent application for a MEAI–PEA combination targeting weight loss and MASLD.
The release cites global prevalence figures (obesity ~890 million adults; MASLD ~30% adults) and market estimates (weight loss drugs ~$37B in 2025, ~$226B by 2035).
SciSparc (Nasdaq: SPRC) announced that its majority-controlled subsidiary NeuroThera Labs (TSXV: NTLX) signed a definitive share purchase agreement to acquire approximately 54.01% of CliniQuantum (CliniQ), a quantum‑technology company focused on quantum simulation for clinical trials.
NeuroThera will issue 56,600,000 common shares valued at about $9,459,954.20 and may pay up to $2,500,000 in earn-outs over three years. Closing is expected on or about March 31, 2026, subject to conditions including an Israeli tax ruling.
SciSparc (Nasdaq: SPRC) will effect a 1-for-9 reverse share split effective at market open on March 4, 2026, reducing issued and outstanding ordinary shares from 5,089,501 to approximately 565,500.
The Ordinary Shares will continue trading under the symbol SPRC on Nasdaq on a split-adjusted basis and will receive a new CUSIP: M82618139. The split was approved June 26, 2025; authorized share capital remains 2,000,000,000 Ordinary Shares. Fractional shares will be rounded at the DTC participant level; options and warrants will be adjusted proportionately.
SciSparc (Nasdaq: SPRC) announced on Feb 2, 2026 that NeuroThera Labs was granted a U.S. patent for a proprietary combination of antimicrobials and cannabinoids designed to potentiate antibiotics versus resistant Gram-positive pathogens such as MRSA.
The patent joins prior U.S. and European grants, is based on preclinical data, and targets a global antibiotics market projected near $58 billion in 2026. SciSparc holds an approximate 75% controlling interest in NeuroThera.
SciSparc (Nasdaq: SPRC) closed the acquisition of an intellectual property portfolio from Xylo Technologies on January 26, 2026, acquiring patents, trademarks and know‑how centered on the single‑use MUSE™ endoscopic system for transoral fundoplication to treat GERD.
Consideration included ordinary shares representing 19.99% of SciSparc and pre‑funded warrants in lieu of some shares. SciSparc intends to commence immediate commercialization and pursue exclusive regional distributor partnerships in North America, Europe and Latin America. The release notes Xylo previously received $3.0M up front in 2019 under a Greater China licensing deal and cites a MarkNtel market estimate valuing the global GERD device market at $2.5B (2024), projected to $3.03B by 2030 (CAGR 3.24% 2025–2030).
SciSparc (Nasdaq: SPRC) signed a definitive agreement to acquire a portfolio of patents, trademarks and know‑how for endoscopic systems and medical cameras, chiefly the MUSE™ single‑use transoral fundoplication device. The Closing is set for March 8, 2026, at which SciSparc will issue ordinary shares that will represent 19.99% of issued and outstanding share capital to Xylo (or pre‑funded warrants in lieu).
SciSparc plans immediate commercialization after closing, aims to replicate Xylo’s 2019 Greater China licensing model (which generated a $3.0M up‑front payment), and cites a GERD device market roughly $2.5B in 2024, projected to $3.03B by 2030.
SciSparc (Nasdaq: SPRC) received a Nasdaq notification that it is not in compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1), which requires at least $2,500,000 in equity. The company reported approximately $(81,000) in stockholders’ equity as of June 30, 2025. SciSparc has 45 calendar days (until February 26, 2026) to submit a plan to regain compliance; if accepted Nasdaq may grant up to a 180-day extension to evidence compliance. The notice has no immediate effect on listing and shares will continue trading as SPRC. The company expects to demonstrate compliance as of December 31, 2025 following proceeds from an $4.2 million debenture conversion in August 2025 and its November 2025 registered direct offering.
SciSparc (Nasdaq: SPRC) said NeuroThera Labs received an Israel patent for a proprietary combination of opioids and N-acylethanolamines designed to potentiate analgesia while reducing side effects.
The grant complements existing patents in Europe, Japan, Australia, and Canada. SciSparc holds a controlling interest of approximately 75% in NeuroThera. A pre-clinical study reported that combining palmitoylethanolamide (PEA) with oxycodone prolonged analgesic effect and reduced some oxycodone-related psychoactive adverse events. The release cites a $5.5–$5.7 billion 2024 global oxycodone market estimate and suggests an "opioid-sparing" effect that may lower required opioid doses.